
Larry Eichenfield, MD: Icotrokinra Demonstrates Promising Results for Adolescents With Moderate to Severe Plaque ...
New data from Johnson & Johnson’s phase 3 ICONIC-LEAD study suggest promise in the treatment of moderate to severe plaque psoriasis in adolescents. Icotrokinra (JNJ-2113), an investigational, first-in-class oral peptide that selectively targets the IL- …